Nurix Therapeutics (NRIX) Stock Statistics & Valuation Metrics

Nurix Therapeutics has a market cap or net worth of $2.37B. The enterprise value is $1.47B.

Nurix Therapeutics has 103,405,815 shares outstanding. The number of shares has decreased by -2.65% in one year.

Nurix Therapeutics’s return on equity (ROE) is -0.49 and return on invested capital (ROIC) is -47.26%.

The current PE Ratio of Nurix Therapeutics is ―. Nurix Therapeutics’s PEG ratio is -0.94.

In the last 12 months, Nurix Therapeutics had revenue of 83.98M and earned -264.46M in profits. Earnings per share was -3.05.

In the last 12 months, operating cash flow was -260.29M and capital expenditures -11.56M, giving a free cash flow of -271.85M billion.

Nurix Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Nurix Therapeutics upcoming earnings date is Jul 9, 2026, After Close (Confirmed).

Nurix Therapeutics as a current ratio of 7.02, with Debt / Equity ratio of 12.20%

In the past 12 months, Nurix Therapeutics has paid 760.00K in taxes.

Nurix Therapeutics EV to EBITDA ratio is -5.20, with an EV/FCF ratio of -4.84.

Nurix Therapeutics has $540.73M in cash and marketable securities with $58.66M in debt, giving a net cash position of $482.08M billion.

Gross margin is -139.43%, with operating margin of -340.16%, and net profit margin of -314.90%.

The average price target for Nurix Therapeutics is $33.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy